OTHER PUBLICATIONS & ABSTRACTS

Other Data


Evidence / Other

Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer: a Decision-Analytic Mode

PUBLICATION: Cancer. 2012 Oct 15;118(20):5163-70. doi: 10.1002/cncr.27443. Epub 2012 Feb 22. AUTHORS: Yang M., Rajan S., Issa A.M. SUMMARY: The model suggested that MammaPrint is a more costโ€effective GEP test compared with Oncotype DX at a threshold willingnessโ€toโ€pay of $50,000 per QALY. Read more: Yang et al_2012_Cancer_Cost Effectiveness of Gene Read More

Head-to-Head Comparison of the 70-gene Signature Versus the 21-Gene Assay: Cost-Effectiveness and the Effect of Compliance

PUBLICATION: Breast Cancer Res Treat. 2012 Jan;131(2):627-36. doi: 10.1007/s10549-011-1769-7. Epub 2011 Sep 24. AUTHORS: Retรจl V.P., Joore M.A., van Harten W.H. SUMMARY: The 21-gene has the highest probability of being cost-effective when focusing on cost/LY, while focusing on cost/QALY, the 70-gene signature was most cost-effective. Read more: Breast Cancer Res Read More

Gene Expression Profiles from Formalin Fixed Paraffin Embedded Breast Cancer Tissue are Largely Comparable to Fresh Frozen Matched Tissue

PUBLICATION: PLoS One. 2011 Feb 11;6(2):e17163. doi: 10.1371/journal.pone.0017163. AUTHORS: Mittempergher L., de Ronde J.J., Nieuwland M., Kerkhoven R.M., Simon I., Rutgers E.J., Wessels L.F., Van't Veer L.J. SUMMARY: We demonstrate that data generated from FFPE material with the DASL assay, if properly processed, are comparable to data extracted from the Read More

Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients with Early Stage Breast Cancer

PUBLICATION: Int J Mol Med. 2010 Dec;26(6):837-43. AUTHORS: Gevensleben H., Gรถhring U.J., Bรผttner R., Heukamp L.C., Kunz G., Dimpfl T., Jackisch C., Ortmann O., Albert U.S., Bender R., De Snoo F., Krijgsman O., Glas A.M., Ergรถnenc Y.H., Vogel C., Dykgers A., Langwieder C., Rees M., Anzeneder T. SUMMARY: Thirty-two percent Read More